Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus

Inclusion criteria

• Men or women with type 2 diabetes mellitus diagnosed at least one year prior to the study with a BMI < 30 kg/m2 , a HbA1C of > 8.0 - < 11.0% at screening
• Fasting serum C-peptide at screening > 0.7 ng/mL
• Subjects who have been on a stable regimen and at the following doses of SU for at least 8 weeks prior to signing informed consent
• Glibenclamide > 5 mg/day
• Glimepiride > 3 mg/day
• Gliclazide > 80 mg/day In addition to receiving the above mentioned SU agents, subjects may have been treated with a biguanide at a stable dose for at least 8 weeks prior to signing informed consent.
• Subjects willing to administer three HMR1964 injections per day immediately prior to meals for a 16 week

Exclusion criteria

• Subjects unwilling or incapable of receiving a starting dose of ≥ 0.2 IU/kg/day of HMR1964
• Subjects with the likelihood of requiring concomitant treatment during the study period with the following classes of drugs: additional OHA (including thiazolidinediones, α-glucosidase inhibitors, D-phenylalanine derivative) other than those specified in the study protocol, insulin preparations other than HMR1964, systemic corticosteroids, other investigational products
• Subjects with clinically relevant cardiovascular, hepatic, neurologic, endocrine diseases; and active cancer; or other major systemic disease making implementation of the protocol or interpretation of the study results difficult
• Subjects who are pregnant, breast feeding or wish to become pregnant during the study period
• Subjects with diabetic retinopathy who received surgical treatments (laser photocoagulation or vitrectomy) within 12 weeks prior to informed consent, who are expected to have these surgical treatments during the study period, or who were diagnosed newly proliferative diabetic retinopathy within 12 weeks prior to informed consent